Wassana Yantasee, PhD, MBA, is a Professor of Biomedical Engineering, Oregon Health and Science University (OHSU) School of Medicine. She graduated from Chulalongkorn University, Thailand with BS (1995) and Oregon State University (OSU) with MS (1999) and PhD in Chemical Engineering (2001) under Prof. Gregory L Rorrer. She also received her MBA in 2001 from OSU.

From 2001-2009, she worked as a research scientist at the Pacific Northwest National Laboratory (PNNL), a US Department of Energy (DOE) National lab. Her last position was SE 4 (two levels below the highest). While at PNNL, she was awarded the Ronald L. Brodzinski Early Career Scientific Achievement Award (2007). In 2014, she was inducted into the Council of Outstanding Early Career Engineers at OSU. 

In October of 2009, she was appointed a faculty position at the Department of Biomedical Engineering, OHSU and as an Oregon Nanomedicine Signature Researcher. Dr. Yantasee is an inventor of 5 US patents and >40 patent applications on nanomaterials for medical and environmental applications. She has authored 7 book chapters and 72 peer-reviewed journal articles, and was named among the top 2% scientists in the world by Stanford University.

She has been a scientific reviewer for over 35 review panels for the National Institutes of Heath (NIH) such as Innovative Research in Cancer Nanotechnology and Biomaterials and Biointerfaces Study Sections as well as for the US Department of Defense (DOD). She also reviewed for international research programs such as the Netherland's Veni-programme, Marie Curie COFUND program, and the French National Research Agency. Dr. Yantasee is the Editor for topical collection of Bioengineering/Nanoparticles in Therapeutic applications and has served as a session chair for multiple international conference programs such as the 7th IEEE International Conference on Nano/Molecular Medicine and Engineering, the 4^th Sustainable Nanotechnology Organization, the 16^th Nanomedicine and Drug Delivery Symposium, and the 17^th Annual Congress of International Drug Discovery Science and Technology. To date, she has mentored over 50 students, interns, and junior scientists. 

Dr. Yantasee is also the founder and CEO of PDX Pharmaceuticals, which has won multiple fast track and phase II SBIR awards from the National Cancer Institute (NCI) on developing novel therapeutics for breast cancer, melanoma, and lung cancer. In collaboration with OHSU, the company is developing cancer nano-immunotherapy as well as vaccines for cancer and Covid-19.